Mark Chin

Mark Chin is an Investment Partner at Avoro Ventures, where he focuses on mid-to-late stage biotechnology and healthcare investments. He brings fifteen years of experience across venture capital, strategy consulting, and corporate development within the life sciences sector. Previously, Chin served as a Managing Director at Arix Bioscience, where he sourced and led ten private biotech investments that ultimately resulted in four initial public offerings, two reverse mergers, and two acquisitions. Before his tenure at Arix Bioscience, he evaluated medical technology opportunities as a venture capital investor and held corporate development and market planning roles at Gilead Sciences and Genentech. Additionally, he gained early strategic experience working as a management consultant at Boston Consulting Group. Chin's professional background centers on identifying and scaling high-potential medical technology and biopharmaceutical companies from initial private funding through public market exits.